Previous 10 | Next 10 |
Keurig Dr Pepper, VICI Properties and ON Semiconductor Set to Join S&P 500; Others to Join S&P MidCap 400, and S&P SmallCap 600 Keurig Dr Pepper, VICI Properties and ON Semiconductor Set to Join S&P 500; Others to Join S&P MidCap 400, and S&P SmallCap 600...
Big changes are afoot in the S&P 500, as Dow Jones Indices shuffles three companies in and out of the index. ON Semiconductor (NASDAQ:ON) is up 6.5% after hours; VICI Properties (NYSE:VICI) is up 6.2%; and Keurig Dr Pepper (NASDAQ:KDP) is up 5.4% postmarket as all three companies make the...
– Other Studies Highlight Impact of Linaclotide in Adult and Pediatric Populations, Highlight Disease Burden – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented new findings during the 2022 Digestive Disease Week ...
– Data to be featured in two oral presentations and six posters – – CEO Tom McCourt to receive American Society for Gastrointestinal Endoscopy (ASGE) President’s Award at meeting – Ironwood Pharmaceuticals, Inc . (Nasdaq: IRWD), a...
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2022 Earnings Conference Call May 5, 2022 08:30 ET Company Participants Matt Roache - Director, Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Conference Call Parti...
Ironwood Pharmaceuticals press release (NASDAQ:IRWD): Q1 Non-GAAP EPS of $0.21. Revenue of $98M. FY22 financial guidance maintained. For further details see: Ironwood Pharmaceuticals Non-GAAP EPS of $0.21, revenue of $98M
– LINZESS ® (Iinaclotide) prescription demand growth increased 11% year-over-year; LINZESS U.S. net sales of $232 million, an increase of 8% year-over-year – – Total revenue of $98 million; U.S. LINZESS collaboration revenue of $94 million &...
Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is $0.26 (+8.3% Y/Y) and the consensus Revenue Estimate is $96.62M (+8.7% Y/Y). Over the last 2 years, IRWD has beaten EPS estimates 75% of ...
Positive interim response for appeal of XPHOZAH received for CKD-PH patients; Advisory Committee could possibly turn things around for possible FDA approval. IBSRELA launched commercially in the United States on April 4, 2022; IBS-C market proven with revenues generated by sales of Li...
Piper Sandler has initiated Ironwood Pharmaceuticals (NASDAQ:IRWD) at overweight citing the success of the company's irritable bowel syndrome drug Linzess (linaclotide). The firm has a $16 price target (~36% upside based on Thursday's close). Analyst David Amsellem said that Linzess has three...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...